Archives
-
Measuring Drug Responses Beyond Cell Viability
2026-10-01
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures in cancer drug testing. By separating growth inhibition from cell killing and considering their timing, the work provides a more informative framework for interpreting in vitro drug responses and designing survivin-focused assays.
-
8-Chloroadenosine for RNA Decay Workflows
2026-10-01
8-Chloroadenosine provides a time-resolved way to suppress RNA synthesis and separate transcriptional input from RNA decay in cell-based assays. This guide translates the reagent into practical workflows for lncRNA, IL-6, and cancer research, with dose-planning, controls, and troubleshooting strategies.
-
Measuring Cancer Drug Responses Beyond Viability
2026-09-30
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify how cancer drugs affect proliferation and cell death. Its central contribution is a more interpretable in vitro response framework that can improve endpoint selection, time-course design, and interpretation of epigenetic cancer studies.
-
TME-Modulating Microspheres Improve TIL Therapy
2026-09-30
Li et al. developed alginate-based microspheres co-loaded with hyaluronidase and CXCL9 to remodel the tumor microenvironment before tumor-infiltrating lymphocyte collection. In mouse models, this pretreatment increased intratumoral TIL abundance, accelerated ex vivo expansion, improved functional properties, and strengthened control of tumor growth and metastasis after reinfusion.
-
Ganetespib Assays: Reading Protein Release Correctly
2026-09-29
Ganetespib (STA-9090) research is usually interpreted through Hsp90 client-protein loss and viability, but extracellular signals require a more careful framework. This article applies lessons from norovirus NINJ1 biology to improve compartment-aware cancer research assays without conflating viral secretion with Hsp90 pharmacology.
-
Lysoptosis: Serpin Control of Lysosomal Cell Death
2026-09-29
The reference study establishes lysoptosis as a conserved lysosome-dependent cell death pathway that becomes prominent when intracellular serpin protection is lost. By connecting genetic models in Caenorhabditis elegans, mouse cells, and human epithelial cells with lysosomal membrane and cathepsin-dependent readouts, it separates lysoptosis from lysosomal damage that merely accompanies other death programs.
-
SkQ1 Separates Mitochondrial Apoptosis from Atrophy
2026-09-28
This preprint uses a metastatic ovarian cancer mouse model to test whether mitochondrial reactive oxygen species, apoptosis, or necroptosis drive skeletal muscle atrophy. Chronic SkQ1 treatment reduced mitochondrial hydrogen peroxide emission and caspase activity in late-stage disease but did not preserve gastrocnemius mass, separating mitochondrial apoptotic signaling from type II B fibre loss.
-
UHRF1, Super-Enhancers, and Osteoporosis
2026-09-28
This study connects UHRF1-dependent DNA 5-methylcytosine, super-enhancer organization, and TGM2-regulated autophagic flux to impaired mesenchymal stem-cell osteogenesis in senile osteoporosis. Its multi-omics and functional strategy suggests a mechanism-linked route for investigating age-related bone loss, while the reported mouse-model rescue remains preclinical.
-
Norepinephrine-to-Angiotensin II Conversion in Shock
2026-09-27
This post-hoc ARAMIS analysis estimated a median norepinephrine-equivalent to angiotensin II conversion ratio of 10:1 for norepinephrine bitartrate in patients with vasodilatory hypotension. The estimate offers a practical reference for critical-care research, but its small, single-center cohort and observational design do not establish a universal dosing rule.
-
L-Alanyl-L-Glutamine: Practical Lab Workflow
2026-09-26
L-Alanyl-L-glutamine is a water-soluble dipeptide for workflows that need a defined alanine–glutamine source and gastrointestinal model support. It is unsuitable for DMSO- or ethanol-based formulations, and aqueous solutions are not recommended for long-term storage; the dossier does not specify assay concentrations or dosing.
-
Chloroquine Diphosphate in AML Ferroptosis Workflows
2026-09-25
Use Chloroquine Diphosphate as a controlled autophagy and lysosomal perturbation alongside—not as proof of—ferroptosis in AML models. This workflow connects the DGLA–ACSL4 findings to practical dose-finding, orthogonal readouts, and troubleshooting for cancer research.
-
CNQX: AMPA/Kainate Blockade in Neuroscience
2026-09-25
CNQX, also known as 6-cyano-7-nitroquinoxaline-2,3-dione, is a competitive AMPA and kainate receptor antagonist used to dissect glutamatergic neurotransmission. A 2024 rat study found that CNQX pretreatment in the paraventricular nucleus did not attenuate the measured cardiovascular responses to chemerin-9 delivered in the caudal nucleus tractus solitarius, unlike NMDA-receptor blockade.
-
BV6 and Cell-Death Assay Interpretation
2026-09-24
BV6 is an IAP antagonist used to investigate apoptosis and treatment sensitization in cancer models. This article connects its reported activity with a key cell-death research finding to show why orthogonal assays and pathway-specific interpretation matter.
-
AAPH Workflows for Protein Oxidation and Stress Assays
2026-09-24
AAPH offers a water-compatible, sustained source of peroxyl-radical stress for protein, erythrocyte, and antioxidant studies. This guide turns a hazelnut-protein finding into practical assay choices, with pilot conditions and troubleshooting clearly distinguished from published results.
-
Carvacrol: Cell-Cycle and TRP Redox Research
2026-09-23
Carvacrol, also known as 5-isopropyl-2-methylphenol, is a research compound with product-documented cell-cycle and apoptosis-related effects. A 2026 study identifies carvacrol as a non-electrophilic TRPA1 agonist that helps distinguish ligand responses from singlet-oxygen-driven channel modification.